Li Yun, Lai Yanzhen, Luo Xuqiang, Wu Jian, Wu Kunpeng, Ma Haiqing
Department of Oncology, Heyuan Hospital of Guangdong Provincial People's Hospital, Heyuan People's Hospital, Heyuan, Guangdong, China.
Heyuan Key Laboratory of Molecular Diagnosis & Disease Prevention and Treatment, Doctors Station of Guangdong Province, Heyuan People's Hospital, Heyuan, Guangdong, China.
Front Oncol. 2024 May 10;14:1291131. doi: 10.3389/fonc.2024.1291131. eCollection 2024.
The five-year recurrence rate of hepatocellular carcinoma (HCC) remains as high as 70%. A complete clinical response has not been observed without surgical resection. Here, we report a rare case of clinical complete response and long-term survival in a patient with massive HCC receiving treatment with immunotherapy, anti-angiogenic therapy, and radiotherapy.
A 38-year-old woman presented to our hospital for abdominal pain that persisted for 3 months. She was diagnosed as Barcelona Clinic Liver Cancer(BCLC) stage A, with a Cancer of the Liver Italian Program (CLIP) score of 3, American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging systems stage IB. She refused surgical resection and trans-arterial chemoembolization and accepted a non-invasive systematic treatment strategy involving immunotherapy, anti-angiogenic therapy, and radiotherapy. Her tumor burden decreased, and she experienced partial response before radiotherapy. Following radiotherapy, she experienced a complete clinical response and has been alive for more than 36 months after her initial presentation. She is currently alive.
A non-invasive systematic treatment strategy is a potential radical treatment option for patients with massive HCC.
肝细胞癌（HCC）的五年复发率仍高达70%。未经手术切除未观察到完全的临床缓解。在此，我们报告一例接受免疫治疗、抗血管生成治疗和放疗的巨大HCC患者出现临床完全缓解和长期生存的罕见病例。
一名38岁女性因持续3个月的腹痛前来我院就诊。她被诊断为巴塞罗那临床肝癌（BCLC）A期，意大利肝癌项目（CLIP）评分为3分，美国癌症联合委员会（AJCC）肿瘤-淋巴结-转移（TNM）分期系统为IB期。她拒绝手术切除和经动脉化疗栓塞，接受了包括免疫治疗、抗血管生成治疗和放疗的非侵入性系统治疗策略。她的肿瘤负荷降低，放疗前出现部分缓解。放疗后，她出现了完全的临床缓解，自首次就诊后已存活超过36个月。她目前仍在世。
非侵入性系统治疗策略是巨大HCC患者潜在的根治性治疗选择。
